Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

Discussion highlights Vat-Ho’s oncology business development experience, his decision to join Akari and the potential of the Company’s novel PH1 payload platform

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.